03 Feb 2025
// FDA
21 Aug 2024
// FDA
05 Aug 2024
// FDA
DATA COMPILATION
#PharmaFlow
About
CPhI North America CPhI North America
Industry Trade Show
Attending
20-22 May, 2025
Industry Trade Show
Booth #E1H39
24-26 June, 2025
Industry Trade Show
Attending
28-30 August, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI North America
Not Confirmed
Contact SupplierCPhI North America
CPhI North America CPhI North America
Industry Trade Show
Attending
20-22 May, 2025
Industry Trade Show
Booth #E1H39
24-26 June, 2025
Industry Trade Show
Attending
28-30 August, 2025
Digital content 
NEWS #PharmaBuzz
03 Feb 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214844
21 Aug 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218205
05 Aug 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218169
15 May 2023
// HEALTH ET
https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/biophore-its-subsidiary-zenara-pharma-receive-first-approval-for-cannabidiol-in-india/100251790
02 May 2023
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212420
04 Apr 2023
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216842
Drugs in Development
Details:
Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 15, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biophore, Its Subsidiary Zenara Pharma, Receive First Approval for Cannabidiol in India
Details : Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 15, 2023
Details:
Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Paxzen
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Zenara Pharma to Launch Generic Paxlovid Soon
Details : Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.
Product Name : Paxzen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2022
Details:
Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Favizen
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zenara Pharma, a Biophore Subsidiary, Gets DCGI Nod for Favipiravir Tablets
Details : Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.
Product Name : Favizen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Details:
Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Favizen
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets
Details : Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.
Product Name : Favizen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
Zenara Pharma
Share 
